{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,3]],"date-time":"2026-05-03T15:12:47Z","timestamp":1777821167278,"version":"3.51.4"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2024,3]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>Optimal use of bone-modifying agents (BMAs) in patients with bone metastases from solid tumors is uncertain in some aspects: the drug choice; the planned treatment duration and long-term therapy; the prevention and management of possible side effects, including renal toxicity, hypocalcaemia, and medication-related osteonecrosis of the jaw (MRONJ).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Italian oncologists were invited to fulfil a 24-question web survey about prescription of BMAs for bone metastases of breast cancer, prostate cancer, and other solid tumors. Prevention and management of side effects were also investigated.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Answers of 191 oncologists were collected. BMAs are usually prescribed at the time of diagnosis of bone metastases by 87.0% (breast cancer) and 76.1% (solid tumors except breast and prostate cancers) of oncologists; the decision is more articulated for prostate cancer (endocrine-sensitive versus castration-resistant). The creatinine level (32.3%), the availability of patient venous access (15.8%), and the type of primary neoplasm (13.6%) are the most reported factors involved in choice between bisphosphonates and denosumab. Zoledronic acid every 3\u00a0months was considered as a valid alternative to monthly administration by 94% of Italian oncologists. Oncologists reported a good confidence with measures aimed to prevent MRONJ, whereas uncertainness about prevention and management of hypocalcemia was registered.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Italian oncologists showed a high attitude in prescribing bisphosphonates or denosumab at the time of diagnosis of bone metastases, with a large application of preventive measures of side effects. Further studies are needed to investigate some controversial aspects, such as optimal drug treatment duration and long-term drug schedules.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00520-024-08392-8","type":"journal-article","created":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T14:02:01Z","timestamp":1709301721000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Treatment of bone metastases from solid tumors with bone-modifying agents: a web survey of Italian oncologists investigating patterns of practice drug prescription and prevention of side effects"],"prefix":"10.1007","volume":"32","author":[{"given":"Vittorio","family":"Fusco","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Massimo","family":"Di Maio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna Amela","family":"Valsecchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniele","family":"Santini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcello","family":"Tucci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ugo","family":"De Giorgi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paolo","family":"Bossi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toni","family":"Ibrahim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luigi","family":"Cavanna","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gaetano","family":"Lanzetta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maura","family":"Rossi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giorgia","family":"Rossetti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mario","family":"Airoldi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandro","family":"Comandone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saverio","family":"Cinieri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,3,1]]},"reference":[{"key":"8392_CR1","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1038\/s41572-020-00216-3","volume":"6","author":"RE Coleman","year":"2020","unstructured":"Coleman RE, Croucher PI, Padhani AR, Cl\u00e9zardin P, Chow E, Fallon M, Guise T, Colangeli S, Capanna R, Costa L (2020) Bone Metastases Nat Rev Dis Prim 6:83","journal-title":"Bone Metastases Nat Rev Dis Prim"},{"key":"8392_CR2","doi-asserted-by":"publisher","first-page":"004","DOI":"10.1016\/j.jbo.2018.10.004","volume":"15","author":"S D'Oronzo","year":"2019","unstructured":"D\u2019Oronzo S, Coleman R, Brown J, Silvestris F (2019) Metastatic bone disease: pathogenesis and therapeutic options: Up-date on bone metastasis management. J Bone Oncol 15:004\u2013004","journal-title":"J Bone Oncol"},{"key":"8392_CR3","doi-asserted-by":"publisher","first-page":"1650","DOI":"10.1016\/j.annonc.2020.07.019","volume":"31","author":"R Coleman","year":"2020","unstructured":"Coleman R, Hadji P, Body JJ, Santini D, Chow E, Terpos E, Oudard S, Bruland \u00d8, Flamen P, Kurth A, Van Poznak C, Aapro M, Jordan K (2020) Bone health in cancer: ESMO Clinical Practice Guidelines. Ann Oncol 31:1650\u20131663","journal-title":"Ann Oncol"},{"key":"8392_CR4","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1200\/JOP.2017.027672","volume":"13","author":"C Van Poznak","year":"2017","unstructured":"Van Poznak C, Somerfield MR, Moy B (2017) Role of bone-modifying agents in metastatic breast cancer: an American Society of Clinical Oncology-Cancer Care Ontario focused guideline update summary. J Oncol Pract 13:822\u2013824","journal-title":"J Oncol Pract"},{"key":"8392_CR5","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1200\/JOP.19.00778","volume":"16","author":"PJ Saylor","year":"2020","unstructured":"Saylor PJ, Rumble RB, Michalski JM (2020) Bone health and bone-targeted therapies for prostate cancer: American Society of Clinical Oncology endorsement summary of a Cancer Care Ontario Guideline. JCO Oncol Pract 16:389\u2013393","journal-title":"JCO Oncol Pract"},{"key":"8392_CR6","doi-asserted-by":"publisher","first-page":"2270","DOI":"10.1200\/JCO.19.01186","volume":"37","author":"N Yarom","year":"2019","unstructured":"Yarom N, Shapiro CL, Peterson DE, Van Poznak CH, Bohlke K, Ruggiero SL, Migliorati CA, Khan A, Morrison A, Anderson H, Murphy BA, Alston-Johnson D, Mendes RA, Beadle BM, Jensen SB, Saunders DP (2019) Medication-related osteonecrosis of the jaw: MASCC\/ISOO\/ASCO clinical practice guideline. J Clin Oncol 37:2270\u20132290","journal-title":"J Clin Oncol"},{"key":"8392_CR7","doi-asserted-by":"publisher","first-page":"X1","DOI":"10.1530\/EC-16-0056a","volume":"8","author":"J Turner","year":"2019","unstructured":"Turner J, Gittoes N, Selby P (2019) Society for endocrinology emergency endocrine guidance: emergency management of acute hypocalcaemia in adult patients. Endocr Connect 8:X1","journal-title":"Endocr Connect"},{"key":"8392_CR8","unstructured":"AIOM - Associazione Italiana Oncologia Medica (2021) Linee guida \u201cMetastasi ossee e salute dell\u2019osso\u201d. Available at https:\/\/www.aiom.it\/linee-guida-aiom-2021-metastasi-ossee-e-salute-dellosso\/. Accessed 26 Feb 2024"},{"key":"8392_CR9","unstructured":"Campisi G, Bedogni A, Fusco V (2020) Raccomandazioni clinico-terapeutiche sull\u2019osteonecrosi delle ossa mascellari (ONJ) farmaco-relata e sua prevenzione. Unipress, Palermo \u2013 Italy. Available at https:\/\/www.sipmo.it\/wp-content\/uploads\/2020\/08\/SICMF-SIPMO-2.0_web-con-cover-2020.pdf. Accessed 26 Feb 2024"},{"key":"8392_CR10","doi-asserted-by":"publisher","first-page":"7047","DOI":"10.1007\/s00520-022-06982-y","volume":"30","author":"V Fusco","year":"2022","unstructured":"Fusco V, Campisi G, Bedogni A (2022) One changing and challenging scenario: the treatment of cancer patients with bone metastases by bisphosphonates and denosumab, the cost-benefit evaluation of different options, and the risk of medication-related osteonecrosis of the jaw (MRONJ). Support Care Cancer 30:7047\u20137051","journal-title":"Support Care Cancer"},{"key":"8392_CR11","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1186\/s12894-018-0393-9","volume":"18","author":"JJ Body","year":"2018","unstructured":"Body JJ, von Moos R, Niepel D, Tombal B (2018) Hypocalcaemia in patients with prostate cancer treated with a bisphosphonate or denosumab: prevention supports treatment completion. BMC Urol 18:81","journal-title":"BMC Urol"},{"key":"8392_CR12","doi-asserted-by":"publisher","first-page":"100420","DOI":"10.1016\/j.jbo.2022.100420","volume":"33","author":"A Jakob","year":"2022","unstructured":"Jakob A, Zahn MO, Nusch A, Werner T, Schnell R, Frank M, Hamm N, D\u00e4\u00dfler KU, Losem C, Welslau M, Hoevel P, Potthoff K (2022) Real-world patient-reported outcomes of breast cancer or prostate cancer patients receiving antiresorptive therapy for bone metastases: final results of the PRO Bone registry study. J Bone Oncol 33:100420","journal-title":"J Bone Oncol"},{"key":"8392_CR13","doi-asserted-by":"publisher","first-page":"116243","DOI":"10.1016\/j.bone.2021.116243","volume":"154","author":"R Von Moos","year":"2021","unstructured":"Von Moos R, Lewis K, Massey L, Marongiu A, Rider A, Seesaghur, (2021) Initiation of bone-targeted agents in patients with bone metastases and breast or castrate-resistant prostate cancer actively treated in routine clinical practice in Europe. Bone 154:116243","journal-title":"Bone"},{"key":"8392_CR14","first-page":"4659","volume":"26","author":"R Berardi","year":"2022","unstructured":"Berardi R, Berruti A, Brogelli L, Zucali PA (2022) An Italian survey on the use of denosumab for the management of skeletal-related events in patients with bone metastases. Eur Rev Med Pharmacol Sci 26:4659\u20134665","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"8392_CR15","doi-asserted-by":"publisher","first-page":"9267","DOI":"10.1007\/s00520-022-07333-7","volume":"30","author":"IJ Diel","year":"2022","unstructured":"Diel IJ, Greil R, Janssen J, Kluike CW, Behera B, Abbasi A, Seesaghur A, Kellner M, Jaeger C, Bjorklof K, Tomova A, Haslbauer F (2022) Medication adherence with denosumab in patients with bone metastases from solid tumors treated in routine clinical settings: a retrospective study. Support Care Cancer 30:9267\u20139278","journal-title":"Support Care Cancer"},{"key":"8392_CR16","doi-asserted-by":"publisher","first-page":"6903","DOI":"10.1007\/s00520-021-06238-1","volume":"29","author":"M Alzahrani","year":"2021","unstructured":"Alzahrani M, Clemons M, Sienkiewicz M, Shrem NS, McGee SF, Vandermeer L, Sehdev S, Savard MF, Awan A, Canil C, Hutton B, Pond G, Saunders D, Ng T (2021) Perceptions around bone-modifying agent use in patients with bone metastases from breast and castration resistant prostate cancer: a patient survey. Support Care Cancer 29:6903\u20136912","journal-title":"Support Care Cancer"},{"key":"8392_CR17","doi-asserted-by":"publisher","first-page":"w20464","DOI":"10.4414\/smw.2021.20464","volume":"151","author":"ST Stoffel","year":"2021","unstructured":"Stoffel ST, von Moos R, Th\u00fcrlimann B, Cathomas R, Gillessen S, Z\u00fcrrer-H\u00e4rdi U, von Briel T, Anchisi S, Feller A, Sch\u00e4r C, Dietrich D, Schwenkglenks M, Lupatsch JE, Mark MT (2021) Patterns of care and economic consequences of using bone-targeted agents for castration-sensitive prostate cancer patients with bone metastases to prevent skeletal-related events in Switzerland - the SAKK 95\/16 prostate study. Swiss Med Wkly 151:w20464","journal-title":"Swiss Med Wkly"},{"key":"8392_CR18","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1186\/s12885-021-07903-8","volume":"21","author":"K Ribi","year":"2021","unstructured":"Ribi K, Th\u00fcrlimann B, Sch\u00e4r C, Dietrich D, Cathomas R, Z\u00fcrrer-H\u00e4rdi U, von Briel T, Anchisi S, Bohanes P, Blum V, von Burg P, Mannhart M, Caspar CB, von Moos R, Mark M (2021) Quality of life and pain in patients with metastatic bone disease from solid tumors treated with bone-targeted agents- a real-world cross-sectional study from Switzerland (SAKK 95\/16). BMC Cancer 21:182","journal-title":"BMC Cancer"},{"key":"8392_CR19","doi-asserted-by":"publisher","first-page":"100339","DOI":"10.1016\/j.jbo.2020.100339","volume":"26","author":"M Alzahrani","year":"2021","unstructured":"Alzahrani M, Clemons M, Vandermeer L, Sienkiewicz M, Awan AA, Hutton B, Pond GR, Ng TL (2021) Real-world practice patterns and attitudes towards de-escalation of bone-modifying agents in patients with bone metastases from breast and prostate cancer: a physician survey. J Bone Oncol 26:100339","journal-title":"J Bone Oncol"},{"key":"8392_CR20","doi-asserted-by":"publisher","first-page":"2175","DOI":"10.1007\/s00520-019-05018-2","volume":"28","author":"H Link","year":"2020","unstructured":"Link H, Diel I, Ohlmann CH, Holtmann L, Kerkmann M (2020) Guideline adherence in bone-targeted treatment of cancer patients with bone metastases in Germany. Support Care Cancer 28:2175\u20132184","journal-title":"Support Care Cancer"},{"key":"8392_CR21","doi-asserted-by":"publisher","first-page":"5223","DOI":"10.1007\/s00520-020-05357-5","volume":"28","author":"I Diel","year":"2020","unstructured":"Diel I, Ansorge S, Hohmann D, Giannopoulou C, Niepel D, Intorcia M (2020) Real-world use of denosumab and bisphosphonates in patients with solid tumours and bone metastases in Germany. Support Care Cancer 28:5223\u20135233","journal-title":"Support Care Cancer"},{"key":"8392_CR22","doi-asserted-by":"publisher","first-page":"1855","DOI":"10.1007\/s00520-019-04988-7","volume":"28","author":"F Haslbauer","year":"2020","unstructured":"Haslbauer F, Petzer A, Safanda M, Tomova A, Porubska M, Bajory Z, Niepel D, Jaeger C, Bjorklof K, Kalinin D, Greil R (2020) Prospective observational study to evaluate the persistence of treatment with denosumab in patients with bone metastases from solid tumors in routine clinical practice: final analysis. Support Care Cancer 28:1855\u20131865","journal-title":"Support Care Cancer"},{"key":"8392_CR23","doi-asserted-by":"publisher","first-page":"100273","DOI":"10.1016\/j.jbo.2019.100273","volume":"21","author":"M Mark","year":"2020","unstructured":"Mark M, Th\u00fcrlimann B, Ribi K, Sch\u00e4r C, Dietrich D, Cathomas R, Z\u00fcrrer-H\u00e4rdi U, von Briel T, Anchisi S, Bohanes P, Blum V, von Burg P, Mannhart M, Caspar CB, von Moos R (2020) Patterns of care for patients with metastatic bone disease in solid tumors: a cross-sectional study from Switzerland (SAKK 95\/16). J Bone Oncol 21:100273","journal-title":"J Bone Oncol"},{"key":"8392_CR24","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1080\/03007995.2018.1558849","volume":"35","author":"D Henry","year":"2019","unstructured":"Henry D, von Moos R, Body JJ, Rider A, De Courcy J, Bhowmik D, Gatta F, Hechmati G, Qian Y (2019) Bone-targeted agent treatment patterns and the impact of bone metastases on patients with advanced breast cancer in the United States. Curr Med Res Opin 35:375\u2013381","journal-title":"Curr Med Res Opin"},{"key":"8392_CR25","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1186\/s12913-018-3272-x","volume":"18","author":"Y Qian","year":"2018","unstructured":"Qian Y, Arellano J, Gatta F, Hechmati G, Hauber AB, Mohamed AF, Bahl A, von Moos R, Body JJ (2018) Physicians\u2019 preferences for bone metastases treatments in France, Germany and the United Kingdom. BMC Health Serv Res 18:518","journal-title":"BMC Health Serv Res"},{"key":"8392_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbo.2018.100212","volume":"14","author":"JJ Body","year":"2019","unstructured":"Body JJ, von Moos R, Rider A, Hallworth P, Bhowmik D, Gatta F, Hechmati G, Qian Y (2019) A real-world study assessing the use of bone-targeted agents and their impact on bone metastases in patients with prostate cancer treated in clinical practice in Europe. J Bone Oncol 14:100212","journal-title":"J Bone Oncol"},{"key":"8392_CR27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jbo.2017.11.004","volume":"11","author":"R Von Moos","year":"2018","unstructured":"Von Moos R, Body JJ, Rider A, de Courcy J, Bhowmik D, Gatta F, Hechmati G, Qian Y (2018) Bone-targeted agent treatment patterns and the impact of bone metastases on patients with advanced breast cancer in real-world practice in six European countries. J Bone Oncol 11:1\u20139","journal-title":"J Bone Oncol"},{"key":"8392_CR28","doi-asserted-by":"publisher","first-page":"638","DOI":"10.3390\/jcm12020638","volume":"12","author":"S Calderaro","year":"2023","unstructured":"Calderaro S, Bausch K, Tourbier C, Wetterauer C, Thieringer FM, Berg BI (2023) Medication-related osteonecrosis of the jaw: a cross-sectional survey among urologists in Switzerland, Germany, and Austria. J Clin Med 12:638","journal-title":"J Clin Med"},{"key":"8392_CR29","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.critrevonc.2019.04.020","volume":"139","author":"A Hussain","year":"2019","unstructured":"Hussain A, Lee RJ, Graff JN, Halabi S (2019) The evolution and understanding of skeletal complication endpoints in clinical trials of tumors with metastasis to the bone. Crit Rev Oncol Hematol 139:108\u2013116","journal-title":"Crit Rev Oncol Hematol"},{"issue":"8","key":"8392_CR30","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1200\/JOP.18.00444","volume":"14","author":"S Leng","year":"2018","unstructured":"Leng S, Lentzsch S (2018) Bone-modifying agents: complicated to use. J Oncol Pract 14(8):469\u2013470. https:\/\/doi.org\/10.1200\/JOP.18.00444","journal-title":"J Oncol Pract"},{"key":"8392_CR31","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1200\/JOP.18.00236","volume":"14","author":"E Campagnaro","year":"2018","unstructured":"Campagnaro E, Reimers MA, Qin A, Alva AS, Schneider BJ, Van Poznak CH (2018) Use of bone-modifying agents in myeloma and bone metastases: how recent dosing interval studies have affected our practice. J Oncol Pract 14:457\u2013464","journal-title":"J Oncol Pract"},{"key":"8392_CR32","doi-asserted-by":"publisher","first-page":"3859","DOI":"10.1007\/s00520-019-04676-6","volume":"27","author":"A Mjelstad","year":"2019","unstructured":"Mjelstad A, Zakariasson G, Valachis A (2019) Optimizing antiresorptive treatment in patients with bone metastases: time to initiation, switching strategies, and treatment duration. Support Care Cancer 27:3859\u20133867","journal-title":"Support Care Cancer"},{"key":"8392_CR33","doi-asserted-by":"publisher","first-page":"4042","DOI":"10.1200\/JCO.2003.08.017","volume":"21","author":"BE Hillner","year":"2003","unstructured":"Hillner BE, Ingle JN, Chlebowski RT, Gralow J, Yee GC, Janjan NA, Cauley JA, Blumenstein BA, Albain KS, Lipton A, Brown S (2003) American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. J Clin Oncol 21:4042\u20134057","journal-title":"J Clin Oncol"},{"key":"8392_CR34","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1007\/s00520-020-05556-0","volume":"29","author":"TL Ng","year":"2021","unstructured":"Ng TL, Tu MM, Ibrahim MFK, Basulaiman B, McGee SF, Srikanthan A, Fernandes R, Vandermeer L, Stober C, Sienkiewicz M, Jeong A, Saunders D, Awan AA, Hutton B, Clemons MJ (2021) Long-term impact of bone-modifying agents for the treatment of bone metastases: a systematic review. Support Care Cancer 29:925\u2013943","journal-title":"Support Care Cancer"},{"key":"8392_CR35","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00520-021-06714-8","volume":"30","author":"M Alzahrani","year":"2022","unstructured":"Alzahrani M, Stober C, Liu M, Awan A, Ng T, Pond G, Alshamsan B, Vandermeer L, Clemons M (2022) Symptomatic skeletal-related events in patients receiving longer term bone-modifying agents for bone metastases from breast and castration resistant prostate cancers. Support Care Cancer 30:1\u20138","journal-title":"Support Care Cancer"},{"key":"8392_CR36","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.joms.2021.09.021","volume":"80","author":"A Bedogni","year":"2022","unstructured":"Bedogni A, Fusco V, Di Fede O, Bettini G, Panzarella V, Mauceri R, Saia G, Campisi G (2022) Re: medication-related osteonecrosis of the jaw (MRONJ). J Oral Maxillofac Surg 80:2\u20133","journal-title":"J Oral Maxillofac Surg"},{"key":"8392_CR37","doi-asserted-by":"publisher","first-page":"1815","DOI":"10.1111\/odi.13160","volume":"25","author":"M Schiodt","year":"2019","unstructured":"Schiodt M, Otto S, Fedele S, Bedogni A, Nicolatou-Galitis O, Guggenberger R, Herlofson BB, Ristow O, Kofod T (2019) Workshop of European task force on medication-related osteonecrosis of the jaw-current challenges. Oral Dis 25:1815\u20131821","journal-title":"Oral Dis"},{"key":"8392_CR38","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1200\/JOP.19.00645","volume":"16","author":"V Fusco","year":"2020","unstructured":"Fusco V, Santini D, Campisi G, Bertoldo F, Lanzetta G, Ibrahim T, Bertetto O, Numico G, Addeo A, Berruti A, Bettini G, Saia G, Bedogni A (2020) Comment on medication-related osteonecrosis of the jaw: MASCC\/ISOO\/ASCO clinical practice guideline summary. JCO Oncol Pract 16:142\u2013145","journal-title":"JCO Oncol Pract"},{"key":"8392_CR39","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1016\/j.joms.2022.07.149","volume":"80","author":"G Campisi","year":"2022","unstructured":"Campisi G, Mauceri R, Bedogni A, Fusco V (2022) Re: AAOMS position paper on medication-related osteonecrosis of the jaw-2022 update. J Oral Maxillofac Surg 80:1723\u20131724","journal-title":"J Oral Maxillofac Surg"},{"key":"8392_CR40","doi-asserted-by":"publisher","first-page":"1871","DOI":"10.1016\/j.joms.2022.07.143","volume":"80","author":"V Fusco","year":"2022","unstructured":"Fusco V, Mauceri R, Campisi G, Bedogni A (2022) RE: American Association of Oral and Maxillofacial Surgeons\u2019 position paper on medication-related osteonecrosis of the jaws-2022 update: quantitative risk assessment and controversial issues. J Oral Maxillofac Surg 80:1871\u20131873","journal-title":"J Oral Maxillofac Surg"},{"key":"8392_CR41","doi-asserted-by":"crossref","unstructured":"Fusco V, Numico G, Alabiso I et al (2023) Personalized (tailored) treatment with antiresorptive drugs (bisphosphonates, denosumab) in patients with bone metastases from solid tumors \u2013 a \u201cPico\u201d document by Rete Oncologica Piemonte-Valle D\u2019Aosta Bone Metastatic Disease Study Group. Qeios. Available at: https:\/\/www.qeios.com\/read\/B83TJ0. Accessed 26 Feb 2024","DOI":"10.32388\/B83TJ0"},{"key":"8392_CR42","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1093\/jnci\/djab216","volume":"114","author":"M Mark","year":"2022","unstructured":"Mark M, von Moos R, Cathomas R, Stoffel S, Gillessen S (2022) RE: real-world use of bone modifying agents in metastatic castration-sensitive prostate cancer. J Natl Cancer Inst 114:635\u2013636","journal-title":"J Natl Cancer Inst"},{"key":"8392_CR43","doi-asserted-by":"publisher","first-page":"4329","DOI":"10.1038\/s41598-021-83749-1","volume":"11","author":"A Bongiovanni","year":"2021","unstructured":"Bongiovanni A, Foca F, Fantini M, Forcignan\u00f2 MR, Artioli F, Berardi R, Campadelli E, Procopio G, Silvestris F, Riva N, Gurrieri L, Debonis SA, Di Menna G, Fausti V, Recine F, Vespignani R, Ibrahim T (2021) First prospective data on breast cancer patients from the multicentre italian bone metastasis database. Sci Rep 11:4329","journal-title":"Sci Rep"},{"key":"8392_CR44","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.ejca.2020.08.019","volume":"142","author":"M Clemons","year":"2021","unstructured":"Clemons M, Ong M, Stober C, Ernst S, Booth C, Canil C, Mates M, Robinson A, Blanchette P, Joy AA, Hilton J, Aseyev O, Pond G, Jeong A, Hutton B, Mazzarello S, Vandermeer L, Kushnir I, Fergusson D (2021) A randomised trial of 4- versus 12-weekly administration of bone-targeted agents in patients with bone metastases from breast or castration-resistant prostate cancer. Eur J Cancer 142:132\u2013140","journal-title":"Eur J Cancer"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-024-08392-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00520-024-08392-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-024-08392-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,19]],"date-time":"2024-03-19T09:28:19Z","timestamp":1710840499000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00520-024-08392-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":44,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["8392"],"URL":"https:\/\/doi.org\/10.1007\/s00520-024-08392-8","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"value":"0941-4355","type":"print"},{"value":"1433-7339","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"8 May 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 February 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 March 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This is a survey not involving patients, so ethics approval is not required.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"The web survey was compiled on a voluntary and anonymous basis, after e-mail invitation, in accordance with national and EU rules on the protection of the processing of personal and sensitive data (European Regulation n.679\/2016, c.d. GDPR, and Italian legislation on Privacy). Therefore, no informed consent was signed because not required.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"MDM reports honoraria from AstraZeneca, Boehringer Ingelheim, Janssen, Merck Sharp & Dohme (MSD), Novartis, Pfizer, Roche, GlaxoSmithKline, Amgen, Merck, Takeda for consultancy or participation to advisory boards and direct research funding from Tesaro\/GlaxoSmithKline, institutional funding for work in clinicaltrials\/contracted research from Beigene, Exelixis, MSD, Pfizer and Roche. D.S. has served on advisory boards for Janssen, Astellas, MSD, Astra-Zeneca, Roche, Merck, Bayer, Novartis, Lilly, Amgen. M.R. has received travel grants by Novartis and Astra Zeneca. P.B. has received a research grant from Amgen. T.I. has received fee for advisory board from Amgen, Pharmamar and GlaxoSmithKline, and partecipation coverage at meeting from Pharmamar and Istituto Gentili. U.D.G. is consultant to Janssen, AstellasPharma, Sanofi, Bayer, Pfizer, Bristol-Myers Squibb, Novartis, Ipsen, Merck; has received institutional funding from Roche, Sanofi, AstraZeneca; and has received travel accommodation from Janssen-Cilag, IPSEN. S.C. is previous\u00a0national AIOM president. Other authors (V.F; M.D.M; A.A.V.; G.R.; G.L.; L.C; M.A.; A.C.) declared to have no relevant financial or non-financial interests to disclose inherent to the paper.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"202"}}